重度哮喘中Muc5AC增加和纤毛细胞减少可被IL-4Rα抑制部分恢复
该研究基于SARPIII队列51例参与者(22例重度哮喘、11例非重度哮喘、18例健康对照)的肺部CT、支气管活检和刷检,发现重度哮喘患者Muc5AC增加、纤毛细胞减少;体外气液界面培养中IL-13可诱导类似重塑,加入dupilumab后纤毛部分恢复,但Muc5AC未显著下降。
要点
- 重度哮喘患者支气管活检显示Muc5AC增加、纤毛细胞减少。
- IL-13体外诱导气道上皮Muc5AC增加和纤毛减少。
- Dupilumab可部分恢复IL-13诱导的纤毛减少,但不显著降低Muc5AC。
核心结论
- IL-13驱动重度哮喘气道重塑特征,体外抑制IL-4Rα可部分逆转。
研究设计与样本
- 研究纳入SARPIII队列51例参与者(22例重度哮喘、11例非重度哮喘、18例健康对照),获取肺部定量CT、支气管活检和刷检。
- 体外将上皮细胞在气液界面(ALI)培养,用IL-13(5 ng/ml)刺激,加或不加dupilumab,评估黏蛋白、纤毛、纤毛摆动频率(CBF)和跨上皮电阻(TEER)。
主要发现
- 重度哮喘患者活检较健康对照Muc5AC增加(Δ + 263.2 ± 92.7 luminosity/epithelial area,P < 0.01),纤毛细胞减少(Δ - 0.07 ± 0.03 Foxj1+ cells/epithelial area,P = 0.047)。
- 支气管刷检RNA测序证实重度哮喘患者Muc5AC增加、五基因纤毛相关均值降低(均P < 0.05)。
- IL-13(5 ng/ml)处理健康人ALI培养增加Muc5AC(Δ + 6.5% ± 1.5%)、减少纤毛(Δ - 14.1% ± 2.7%),均P < 0.001;哮喘患者样本Muc5AC增加(Δ + 4.4% ± 2.5%,P = 0.084)、纤毛减少(Δ - 13.1% ± 2.7%,P < 0.001)。
- IL-13处理健康人样本降低TEER(-140.9 ± 21.3 ohms,P < 0.001),哮喘患者样本降低CBF(Δ - 4.4 ± 1.7 Hz,P < 0.01)。
- 加入dupilumab后Muc5AC无显著下降,但健康人和哮喘患者纤毛恢复(绝对增加67.5%和32.5%,均P < 0.05),CBF增加(Δ + 3.6 ± 1.1 Hz,P < 0.001),TEER仅在哮喘中降低(Δ - 37.8 ± 16.2 ohms,P < 0.05)。
临床怎么用
- 提示IL-13/IL-4Rα通路参与重度哮喘气道重塑,dupilumab可能部分改善纤毛功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: The role of IL-13 on the airway epithelium in severe asthma leading to airway remodeling remains poorly understood. Objectives: To study IL-13-induced airway remodeling on goblet cells and cilia in the airway epithelium in severe asthma and the impact of an anti-IL4Rα antibody, dupilumab, in vitro. Methods: Quantitative computed tomography of the lungs and endobronchial biopsies and brushings were obtained in 51 participants (22 with severe asthma, 11 with nonsevere asthma, and 18 healthy participants) in SARPIII (Severe Asthma Research Program III) and measured for mucin and cilia-related proteins. Epithelial cells were differentiated at air-liquid interface (ALI) with IL-13 with or without dupilumab and assessed for mucin, cilia, cilia beat frequency (CBF), and epithelial integrity (transepithelial electrical resistance [TEER]). Measurements and Main Results: Increased Muc5AC (mucin 5AC) (Δ + 263.2 ± 92.7 luminosity/epithelial area) and decreased ciliated cells (Δ - 0.07 ± 0.03 Foxj1+ cells/epithelial area) were observed in biopsies from patients with severe asthma when compared with healthy control subjects (P < 0.01 and P = 0.047, respectively). RNA sequencing of endobronchial cell brushings confirmed a Muc5AC increase with a decrease in a five-gene cilia-related mean in patients with severe asthma compared with healthy subjects (all P < 0.05). IL-13 (5 ng/ml)-differentiated ALI cultures of healthy and asthmatic samples (from participants with severe and nonsevere asthma) increased Muc5AC, decreased cilia (α-aceytl-tubulin) in samples from healthy participants (Δ + 6.5% ± 1.5%, Δ - 14.1% ± 2.7%; all P < 0.001 respectively) and participants with asthma (Δ + 4.4% ± 2.5%, Δ - 13.1% ± 2.7%; P = 0.084, P < 0.001 respectively), and decreased epithelial integrity (TEER) in samples from healthy participants (-140.9 ± 21.3 [ohms], P < 0.001), while decreasing CBF in samples from participants with asthma (Δ - 4.4 ± 1.7 [Hz], P < 0.01). When dupilumab was added to ALI with IL-13, there was no significant decrease in Mu5AC, but there was restoration of cilia in healthy participants and participants with asthma (absolute increase of 67.5% and 32.5% cilia, all P < 0.05, respectively), whereas CBF increased (Δ + 3.6 ± 1.1 [Hz], P < 0.001) and TEER decreased (only in asthma, Δ - 37.8 ± 16.2 [ohms], P < 0.05). Conclusions: IL-13 drives features of airway remodeling in severe asthma, which are partially reversed by inhibiting the IL-4Rα receptor in vitro.
引用
- Boomer J, Choi J, Alsup A, et al. Increased Muc5AC and Decreased Ciliated Cells in Severe Asthma Partially Restored by Inhibition of IL-4Rα Receptor. Am J Respir Crit Care Med. 2024. PMID: 38935626. doi:10.1164/rccm.202307-1266OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。